ABSTRACT
Evaluation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) usage in heart failure (HF) patients with or without type 2 diabetes mellitus (T2DM) could be proven to be a critical breakthrough in treatment options available for these patients. Our study focuses on understanding the safety and efficacy of GLP-1 RAs in this patient population by pooling the data from 9 randomized controlled trials (RCTs) comprising 871 subjects. As compared with the placebo, GLP-1 RAs did not improve major adverse cardiovascular events (MACE) which include cardiovascular (CV) mortality and heart failure (HF) hospitalizations, our primary outcome. CV mortality (RRâ¯=â¯1.03, 95% CIâ¯=â¯0.56-1.88, Pâ¯=â¯0.92) and HF hospitalizations (RRâ¯=â¯1.18, 95%CIâ¯=â¯0.93-1.51, Pâ¯=â¯0.18). Similarly, GLP-1 RAs did not improve our secondary findings of left ventricular ejection fraction (LVEF) and 6-minute walk test (6MWT). LVEF (RRâ¯=â¯1.96, 95%CIâ¯=â¯-0.16-4.07, Pâ¯=â¯0.07) or 6 MWT (RRâ¯=â¯8.43, 95% CIâ¯=â¯-2.69-19.56, Pâ¯=â¯0.14). This meta-analysis shows that GLP-1 RAs do not improve cardiovascular outcomes in HF patients with or without T2DM.
